Cannabinoids have been shown to exert a neuroprotective influence in organophosphorus-induced toxicity. In our study, we examined the effects of the cannabinoid receptor agonist WIN55,212-2 and NMDA receptor agonist NMDA on cell death in the pheochromocytoma cell line PC12 subjected to the action of an organophosphorus compound, diazinon. Diazinon decreased cell viability in a concentration-dependent manner. Following the exposure of PC12 cells to 200 μM diazinon for 48 h, reductions in cell survival and protein level of CB1 receptors were observed. Treatment of the cells with 0.1 μM WIN55,212-2 and 100 μM NMDA prior to diazinon exposure significantly elevated the cell survival level and protein level of CB1 receptors. The cannabinoid antagonist AM251 (1 μM) did not inhibit the neuroprotection effect induced by WIN55,212-2, indicating that the neuroprotective effect of this agonist was cannabinoid receptor-independent. The NMDA receptor antagonist MK-801 (1 μM) enhanced diazinon-mediated neurotoxicity suggesting that precisely NMDA receptors may play a protective role.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
S. J. Garfitt, K. Jones, H. J. Mason, and J. Cocker, “Exposure to the organophosphate diazinon: data from a human volunteer study with oral and dermal doses,” Toxicol. Let., 134, Nos. 1/3, 105-113 (2002).
H. Mehrani and L. Golmanesh, “Changes in mRNA and protein levels of nicotinic acetylcholine receptors in Diazoxon-exposed PC12 cells,” Toxicol. in vitro, 22, No. 5, 1257-1263 (2008).
T. L. Lassiter, E. A. MacKillop, I. T. Ryde, et al., “Is fipronil safer than chlorpyrifos? Comparative developmental neurotoxicity modeled in PC12 cells,” Brain Res. Bull., 78, No. 6, 313-322 (2009).
S. Sadri, F. Bahrami, M. Khazaei, et al., “Cannabinoid receptor agonist WIN55,212-2 protects differentiated PC12 cells from organophosphorus-induced apoptosis,” Int. J. Toxicol., 29, No. 2, 201-208 (2010).
J. Flaskos, W. Harris, M. Sachana, et al., “The effects of diazinon and cypermethrin on the differentiation of neuronal and glial cell lines,” Toxicol. Appl. Pharmacol., 219, Nos. 2/3, 172-180 (2007).
E. Nocerino, M. Amato, and A. A. Izzo, “Cannabis and cannabinoid receptor,” Fitoterapia, 71, S6-S12 (2000).
I. Svízenská, P. Dubový, and A. Sulcová, “Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures – a short review,” Pharmacol. Biochem. Behav., 90, No. 4, 501-511 (2008).
D. Baker, G. Pryce, G. Giovannoni, and A. J. Thompson, “The therapeutic potential of Cannabis,” Lancet Neurol., 2, No. 5, 291-298 (2003).
B. G. Ramírez, C. Blázquez, T. Gómez del Pulgar, et al., “Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation,” J. Neurosci., 25, No. 8, 1904-1913 (2005).
M. Hashemi, F. Bahrami, H. Sahraei, et al., “The neuroprotective effect of cannabinoid receptor agonist (WIN55,212-2) in paraoxon induced neurotoxicity in PC12 cells and N-methyl-D-aspartate receptor interaction,” Cell J., 12, No. 2, 183-190 (2010).
C. Sommer, M. Schomacher, C. Berger, et al., “Neuroprotective cannabinoid receptor antagonist SR141716-A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra,” Acta Neuropathol., 112, No. 3, 277-286 (2006).
J.G. Barbara, N. Auclair, M. P. Roisin, et al., “Direct and indirect interactions between cannabinoid CB1 receptor and group ΙΙ metabotropic glutamate receptor signaling in layer V pyramidal neurons from the rat prefrontal cortex,” Eur. J. Neurosci., 17, No. 5, 981-990 (2003).
F. Boscia, F. Ferraguti, F. Moroni, et al., “mGlu1α receptors are co-expressed with CB1 receptors in a subset of interneurons in the CA1 region of organotypic hippocampal slice cultures and adult rat brain,” Neuropharmacology, 55, No. 4, 428-439 (2008).
K. P. Sarker, and I. Maruyama, “Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts,” Cell. Mol. Life Sci., 60, No. 6, 1200-1208 (2003).
G. J. Molderings, H. Bönisch, R. Hammermann, et al., “Noradrenaline release-inhibiting receptors on PC12 cells devoid of α2 and CB1 receptors: similarities to presynaptic imidazoline and EDG receptors,” Neurochem. Int. 40, No. 2, 157-167 (2002).
M. Casado, A. López-Guajardo, B. Mellström, et al., “Functional N-methyl-D-aspartate receptors in clonal rat pheochromocytoma cells,” J. Physiol., 490, No. 2, 391-404 (1996).
M. M. Bradford, “A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,” Anal. Biochem., 72, 248-254 (1976).
F. Bahrami, M. Yousefpour, H. Mehrani, et al., “Type of cell death and the role of acetylcholinesterase activity in neurotoxicity induced by paraoxon in cultured rat hippocampal neurons,” Acta Biol. Hung., 60, No. 1, 1-13 (2009).
T. A. Slotkin and F. J. Seidler, “Developmental neurotoxicants target differentiation into the serotonin phenotype: chlorpyrifos, diazinon, dieldrin and divalent nickel,” Toxicol. Appl. Pharmacol., 233, No. 2, 211-219 (2008).
J. Chen, C. Lee, S. Errico, et al., “Protective effects of Δ9-tetrahydrocannabinol against N-methyl-D-aspartateinduced AF5 cell death,” Mol. Brain Res., 134, No. 2, 215-225 (2005).
T. Iuvone, G. Esposito, R. Esposito, et al., “Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells,” J. Neurochem., 89, No. 1, 134-141 (2004).
D. Fernández-López, J. Martínez-Orgado, E. Nuñez, et al., “Characterization of the neuroprotective effect of the cannabinoid agonist WIN55,212-2 in an in vitro model of hypoxic-ischemic brain damage in newborn rats,” Pediatr. Res., 60, No. 2, 169-173 (2006).
B. S. Harvey, K. S. Ohlsson, J. L. Mååg, et al., “Contrasting protective effects of cannabinoids against oxidative stress and amyloid-b evoked neurotoxicity in vitro,” Neurotoxicology, 33, No. 1, 138-146 (2012).
T. Gomes del Pulgar, G. Velasco, and M. Guzmán, “The CB1 cannabinoid receptor is coupled to the activation of protein kinaseB/Akt,” Biochem. J., 347, No. 2, 369-373 (2000).
M. Guzmán, C. Sánchez, and I. Galve-Roperh, “Cannabinoids and cell fate,” Pharmacol. Therapeut., 95, No. 2, 175-184 (2002).
M. Widmer, C. O. Hanemann, and J. Zajicek, “High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells,” J. Neurosci. Res., 86, No. 14, 3212-3220 (2008).
V. See, A. L. Boutillier, H. Bito, and J. P. Loeffler, “Calcium/calmodulin dependent protein kinase type IV (CaMKIV) inhibits apoptosis induced by potassium deprivation in cerebellar granule neurons,” FASEB. J., 15, No. 1, 134-144 (2001).
X. Xifro, A. Falluel-Morel, A. Minano, et al., “N-methyl-D-aspartate blocks activation of JNK and mitochondrial apoptotic pathway induced by potassium deprivation in cerebellar granule cells,” J. Biol. Chem., 281, No. 10, 6801-6812 (2006).
D. Jantas and W. D. Lason, “Different mechanisms of NMDA mediated protection against neuronal apoptosis: a stimuli-dependent effect,” Neurochem. Res., 34, No. 11, 2040-2054 (2009).
J. Singh and G. Kaur, “Neuroprotection mediated by subtoxic dose of NMDA in SH-SY5Y neuroblastoma cultures: activity dependent regulation of PSA-NCAM expression,” Brain Res. Mol., 137, Nos. 1/2, 223-234 (2005).
C. C. Wang, R. G. Held, S. C. Chang, et al., “A critical role for GluN2B-containing NMDA receptors in cortical development and function,” Neuron, 72, No. 5, 789-805 (2011).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bahrami, F., Hashemi, M., Khalili, F. et al. Stimulation of CB1 Cannabinoid and NMDA Receptors Increases Neuroprotective Effect against Diazinon-Induced Neurotoxicity. Neurophysiology 45, 433–440 (2013). https://doi.org/10.1007/s11062-013-9390-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11062-013-9390-5